Zimmer Holdings To List Stock On NYSE
July 28, 2016 at 4:25 p.m.
Zimmer Holdings Inc. announced Monday that it has received the necessary clearances from the New York Stock Exchange and the Securities and Exchange Commission to list its common stock on the New York Stock Exchange.
It is anticipated that the spin-off will be effective Aug. 6 to record holders of Bristol-Myers Squibb common stock as of July 27.
"We are very excited about the opportunity to operate Zimmer as an independent public company and to continue to strengthen Zimmer's position as a global leader in orthopedics. Zimmer's recent financial performance has been excellent, and we plan to continue to achieve strong sales growth in our current product categories and to pursue opportunities to leverage our brand and sales force in high-growth adjacent orthopedic product categories," said Ray Elliott, president and CEO of Zimmer Holdings Inc.
Zimmer management estimates that overall revenue growth in 2001 and 2002 will approximate 8 to 11 percent, with sales of reconstructive implants expected to grow 10 to 13 percent and sales of fracture management products expected to grow at an average of 6 to 9 percent. [[In-content Ad]]
Latest News
E-Editions
Zimmer Holdings Inc. announced Monday that it has received the necessary clearances from the New York Stock Exchange and the Securities and Exchange Commission to list its common stock on the New York Stock Exchange.
It is anticipated that the spin-off will be effective Aug. 6 to record holders of Bristol-Myers Squibb common stock as of July 27.
"We are very excited about the opportunity to operate Zimmer as an independent public company and to continue to strengthen Zimmer's position as a global leader in orthopedics. Zimmer's recent financial performance has been excellent, and we plan to continue to achieve strong sales growth in our current product categories and to pursue opportunities to leverage our brand and sales force in high-growth adjacent orthopedic product categories," said Ray Elliott, president and CEO of Zimmer Holdings Inc.
Zimmer management estimates that overall revenue growth in 2001 and 2002 will approximate 8 to 11 percent, with sales of reconstructive implants expected to grow 10 to 13 percent and sales of fracture management products expected to grow at an average of 6 to 9 percent. [[In-content Ad]]